Literature DB >> 26202150

Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049).

Ernesto Bosch1, Anders Nyboe Andersen2, Pedro Barri3, Juan Antonio García-Velasco4, Petra de Sutter5, Manuel Fernández-Sánchez6, Hana Visnova7, Bjarke M Klein8, Bernadette Mannaerts9, Joan-Carles Arce9.   

Abstract

OBJECTIVE: To study the association between serum anti-Müllerian hormone (AMH) levels and follicular development and endocrine responses induced by increasing doses (5·2-12·1 μg/day) of a novel recombinant human FSH (rhFSH, FE 999049) in patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in a GnRH antagonist protocol.
DESIGN: Secondary analysis of a randomized controlled trial with stratified randomization according to AMH (lower stratum: 5·0-14·9 pmol/l; higher stratum: 15·0-44·9 pmol/l). PATIENTS: Infertile women of good prognosis (n = 265). MEASUREMENTS: Follicular development and endocrine parameters during controlled ovarian stimulation (COS) with rhFSH.
RESULTS: Serum FSH levels increased with increasing rhFSH doses and steady-state levels for each dose were similar in both AMH strata. In the whole study population, significant (P < 0·001) positive dose responses were observed for the number of follicles ≥ 12 mm, and serum levels of oestradiol, inhibin B, inhibin A and progesterone at end of stimulation. In comparison with the higher AMH stratum, patients in the lower AMH stratum had significantly different slopes of the dose-response curves for these hormones, and no clear dose-related increase was observed for the number of follicles in these patients.
CONCLUSIONS: Dose-response relationships between rhFSH and follicular development and endocrine parameters are significantly different for IVF/ICSI patients with lower and higher serum AMH levels at start of COS.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202150     DOI: 10.1111/cen.12864

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Comparative pharmacology of a new recombinant FSH expressed by a human cell line.

Authors:  Wolfgang Koechling; Daniel Plaksin; Glenn E Croston; Janni V Jeppesen; Kirsten T Macklon; Claus Yding Andersen
Journal:  Endocr Connect       Date:  2017-04-27       Impact factor: 3.335

Review 2.  Recent advancement in the treatment of boys and adolescents with hypogonadism.

Authors:  Rodolfo A Rey
Journal:  Ther Adv Endocrinol Metab       Date:  2022-01-05       Impact factor: 3.565

3.  Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing.

Authors:  Stamatina Iliodromiti; Barbara Salje; Didier Dewailly; Craig Fairburn; Renato Fanchin; Richard Fleming; Hang Wun Raymond Li; Krzysztof Lukaszuk; Ernest Hung Yu Ng; Pascal Pigny; Teddy Tadros; Joseph van Helden; Ralf Weiskirchen; Scott M Nelson
Journal:  Hum Reprod       Date:  2017-08-01       Impact factor: 6.918

4.  FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation.

Authors:  Ali Abbara; Aaran Patel; Tia Hunjan; Sophie A Clarke; Germaine Chia; Pei Chia Eng; Maria Phylactou; Alexander N Comninos; Stuart Lavery; Geoffrey H Trew; Rehan Salim; Raj S Rai; Tom W Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-27       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.